Business Wire

Algorand and BridgeTower Capital Announce Strategic Partnership

15.4.2021 23:14:00 EEST | Business Wire | Press release

Share

BridgeTower Capital, a global private equity firm, focusing on traditional private equity investments and blockchain and DeFi markets, announced today a partnership with Algorand. Algorand, the creator of the world’s first pure proof-of-stake foundational blockchain, is a leading blockchain technology company accelerating the convergence of decentralized and traditional finance.

BridgeTower will use Algorand’s technology as the underlying blockchain solution to issuance of the BridgeTower Capital tokenized digital security. It will also use Algorand as a preferred blockchain for BridgeTower products and services. Beyond the elementary requirement of an open, public network, Algorand’s technology enables a set of high performing Layer-1 blockchains that provide security, scalability, complete transaction finality, built in privacy, Co-Chains, and advanced smart contracts.

“Algorand was a clear choice given their technology, team and leadership position in the digital marketplace,” said BridgeTower Chief Executive Officer Cory Pugh. “It is another important piece falling into place our effort to bring a new-world vision to private equity to maximizing the growing opportunities in blockchain and DeFi in private equity. It’s gratifying to see it coming together and to now see others enthusiastically validating the vision.”

BridgeTower is bringing a traditional operational business approach to its decentralized finance business by building recurring revenue and EBITDA growth as well as providing funding to growth companies with to create increased valuations. BridgeTower’s current blockchain staking product has grown substantially to more than $60 million assets under delegation within two months of launch. BridgeTower will aggressively add self-hosted Nodes over the coming months. “Algorand’s partnership with BridgeTower is based on our aligned vision to provide access to decentralized assets and products as well as a shared focus to expand opportunities in financial services through advanced blockchain technology,” said David Markley, Business Solutions at Algorand. “We are excited BridgeTower will be leveraging Algorand to allow investors to become shareholders in their tokenized private equity firm and admire their leadership in tokenized security offerings.”

Today, nearly 1 million transactions per day are posted on Algorand’s blockchain. In addition, over 4.5 million assets have been issued on chain and more than 500 companies are currently developing applications on Algorand, taking advantage of the unique layer-1 smart contracts and the other functionalities enriching the platform.

This past month BridgeTower also announced it has formed a Zurich-based entity to further expand its current products and partnerships.

ABOUT BRIDGETOWER CAPITAL – BridgeTower Capital is a global tokenized Private Equity firm with a traditional operational business mentality of building strong revenue and EBITDA growth. BridgeTower shareholders have access to opportunities in decentralized finance (DeFi) built on blockchain technology. In addition, BridgeTower’s private equity investments in early to mid-stage growth companies provides financial, operational, talent acquisition and marketing support. For more information, visit https://www.bridgetowercapital.com/

ABOUT ALGORAND – Algorand is building the technology to power the Future of Finance (FutureFi), the convergence of traditional and decentralized models into a unified system that is inclusive, frictionless, and secure. Founded by Turing Award-winning cryptographer Silvio Micali, Algorand developed a blockchain infrastructure that offers the interoperability and capacity to handle the volume of transactions needed for decentralized finance (DeFi), financial institutions, and governments to smoothly transition into FutureFi. The technology of choice for more than 500 global organizations, Algorand is enabling the simple creation of next-generation financial products, protocols and exchange of value. For more information, visit www.algorand.com

Disclaimer

This is not an offer to sale or purchase securities in BridgeTower. Any securities offered by BridgeTower are offered pursuant to a Confidential Private Placement Memorandum to accredited investors only in accordance with an exemption from registration provided by Rule 506(c) of Regulation D of the Securities Act. BridgeTower is not under any obligation to make an offering. Any indications of interest in BridgeTower involves no obligation or commitment of any kind. Past performance is not indicative of future success. Statements about the expected timing, and all other statements in this press release, other than historical facts, constitute forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date hereof and are based on current expectation and involve a number of assumptions, risks and uncertainties that could cause actual results to differ materially from those projected. A number of the matters discussed herein that are not historical or current facts deal with potential future circumstances and developments that may or may not materialize. This press release speaks only as of its date, and except as required by law, we disclaim any duty to update.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

BridgeTower Contact:
Todd Wolfenbarger / todd@summitslc.com

Chairman and CEO:
Cory Pugh / cory@bridgetowercapital.com

Algorand Contact:
Keli Callaghan / keli@algorand.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism Journal5.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced the publication of clinical data from its Phase 2 (RAINBOW) study in the peer reviewed journal, Molecular Genetics & Metabolism. The published manuscript reports efficacy, safety, pharmacokinetic and pharmacodynamic data which evaluated nizubaglustat in patients with genetically confirmed GM2 gangliosidosis and NPC. As previously stated in the topline results announcement in July 2024, the RAINBOW study met its primary objective of demonstrating that nizubaglustat was safe and well tolerated. The study also showed encouraging signs of clinical efficacy, reducing disease progression and seizure burden in patients treated with nizubaglustat. “The publication of the RAINBOW data in a peer-reviewed journal represents an important milestone for Azafaros and for the broader lysosomal disease community,” said Stefano Portolano,

K-Startup Grand Challenge 2026: Korea's Full-Cycle Launchpad for Global Startups5.6.2026 04:00:00 EEST | Press release

South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for the K-Startup Grand Challenge (KSGC), the country’s premier government-backed acceleration program for international startups targeting Korea and Asia. Since 2016, KSGC has attracted 21,537 applicants from more than 100 countries, among the world's most recognized inbound programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604794426/en/ South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for K-Startup Grand Challenge 2026, a government-backed global startup acceleration program providing end-to-end support for international startups (Image: KSGC) A Full-Cycle Acceleration Journey Unlike conventional programs that focus on a single moment of market entry, KSGC 2026 guides startups from market entry to scale up in Korea - offered in a hybrid format - online or in person - with Demo Day held in Korea. The program runs Jul

Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More5.6.2026 00:46:00 EEST | Press release

The Empire State Building Observation Deck (ESB) – the #1 Attraction in the United States – today announced further 2026 programming for soccer fans in New York City with the world’s most iconic jersey collection from the Classic Football Shirts (CFS) vault, a limited-edition ESB x CFS jersey, official merch giveaways, and special lightings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604370013/en/ Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More “As the world descends upon New York City for this anticipated global soccer event, fans can visit the Empire State Building Observation Deck for Manhattan’s best skyline views and a one-of-a-kind soccer exhibit,” said Dan Rogoski, observatory general manager. “International and American soccer fans can extend the celebration off the pitch at the #1 Attraction in the

Vycellix to Provide Universal Cell Cancer Therapy Progress Reports at Upcoming Investor & Partnering Meetings4.6.2026 21:15:00 EEST | Press release

Vycellix, Inc., a biotechnology company developing next-generation allogeneic natural killer (NK) cell-based therapies designed to overcome the risk of immune rejection and redefine functional persistence with durability, today announced the Company will attend a series of upcoming investor and partnering meetings to share progress reports on the Company’s universal cell therapy platforms and product candidates targeting multiple myeloma, acute myeloid leukemia and urothelial cancers. Vycellix is attending: June 8-9: U.S. Department of Commerce Certified Trade Mission to Norway in Oslo June 11-14: European Hematology Association (EHA) 2026 Congress in Stockholm June 22-25: BIO International Convention in San Diego (Florida Pavilion, Booth# 1319) To request a meeting with Vycellix at any of these events, please contact Doug Calder at dcalder@vycellix.com. Vycellix recently announced the successful completion of pre-clinical development for its universal cell engineering platform (VY-UC)

Sodali & Co Appoints Fabio Bianconi as Head of Italy4.6.2026 20:15:00 EEST | Press release

Sodali & Co, the leading global capital markets-centric stakeholder advisory firm, today announced the appointment of Fabio Bianconi as Head of Italy, effective immediately. Fabio succeeds Andrea Di Segni, who will transition into a new role as Senior Relationship Advisor, where he will continue to support key client relationships and strategic initiatives across the firm. Fabio brings deep experience, strong client relationships, and a track record advising on complex mandates in the Italian market. He will lead Sodali’s continued growth and development in Italy, building on the firm’s established position in the region. Aneliya Crawford, Chief Partnerships Officer & Global Head of Shareholder Advisory of Sodali & Co, said: “Andrea has played a central role in the evolution of Sodali over more than two decades, helping establish the firm as a trusted global advisor in corporate governance and shareholder engagement. He built our Italian business into a leader in the market, as reflect

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye